Showing results (11-20 of 226) with videos related to
Sort By:
Pageof 23
Journal of Medicinal Chemistry|February 1, 1990
Beta-lactam analogues of oxotremorine. 3- and 4-methyl-substituted 2-azetidinonesB M Nilsson, B Ringdahl, U HacksellPharmacology & Toxicology|May 1, 1995
Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents?U Hacksell, D M Jackson, N MohellJournal of Medicinal Chemistry|March 1, 1988
Derivatives of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamideB M Nilsson, B Ringdahl, U HacksellJournal of Medicinal Chemistry|August 21, 1992
Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamideB M Nilsson, H M Vargas, U HacksellChirality|December 5, 1998
Stereoisomers of 3-(2,3-dihydrobenzofuran-2-yl)quinuclidine: preparation and muscarinic receptor affinitiesG Johansson, M Brisander, S Sundquist, et al.European Journal of Pharmacology|September 4, 1991
The novel 5-HT1A receptor antagonist (S)-UH-301 antagonizes 8-OH-DPAT-induced effects on male as well as female rat copulatory behaviourC E Johansson, B J Meyerson, U HacksellEuropean Journal of Pharmacology|July 9, 1991
(S)-UH-301 antagonizes (R)-8-OH-DPAT-induced cardiovascular effects in the ratL Björk, S Lindgren, U Hacksell, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 1, 1992
Effects of (R)-8-OH-DPAT and the enantiomers of UH-301 on motor activities in the rat: antagonism of (R)-8-OH-DPAT-induced effectsL Björk, A Fredriksson, U Hacksell, et al.The Journal of Pharmacy and Pharmacology|January 1, 1996
Oral cavity absorption of (R)-8-hydroxy-2-(di-n-propylamino)tetralin and (S)-8-acetyl-2-(di-n-propylamino)tetralin in the ratH Yu, Y Liu, U Hacksell, et al.Journal of Medicinal Chemistry|April 1, 1989
Topography and conformational preferences of 6,7,8,9-tetrahydro-1-hydroxy-N,N-dipropyl-5H-benzocyclohepten-6- ylamin e. A rationale for the dopaminergic inactivityA Karlén, A Helander, L Kenne, et al.Pageof 23